West Pharmaceutical resumed with an Overweight at Stephens

Stephens resumed coverage of West Pharmaceutical (WST) with an Overweight rating and $250 price target The firm calls West “a high-quality, industry leading provider of containment solutions and services for injectable medications that is positioned to win within the defensive healthcare and life sciences industries.” The company is targeting 7%-9% organic growth along with 100 basis points of margin expansion annually as industry tailwinds – including biologics, GLP-1s, and stricter regulatory requirements – drive higher volumes and demand for high value components, the analyst tells investors.